Zoetis Inc. $ZTS Stock Holdings Increased by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 126.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,470,742 shares of the company’s stock after acquiring an additional 822,334 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Zoetis were worth $229,362,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. lifted its position in shares of Zoetis by 0.8% in the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after purchasing an additional 330,823 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Zoetis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares in the last quarter. Polen Capital Management LLC boosted its holdings in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. Northern Trust Corp increased its stake in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after purchasing an additional 78,508 shares during the period. Finally, Norges Bank acquired a new position in shares of Zoetis during the second quarter worth approximately $809,491,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 2.2%

Shares of NYSE:ZTS opened at $124.44 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company’s 50-day moving average price is $135.06 and its two-hundred day moving average price is $148.47. The stock has a market capitalization of $54.84 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a one year low of $115.25 and a one year high of $181.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st were paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.6%. The ex-dividend date was Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ZTS. Morgan Stanley lowered their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. Argus reaffirmed a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. BTIG Research dropped their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a report on Wednesday, November 12th. Finally, Stifel Nicolaus decreased their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.